2019 Presentations

The state of cancer care in 2019
Charles Balch
Hematologic Malignancies
The state of cancer care in 2019
Julie Vose
Myelodysplastic Syndromes (MDS): The right treatments for the right patients
Naval Daver
Acute Myelogenous Leukemia (AML): Making sense of the options
Naval Daver
Diffuse Large B-Cell Lymphoma: Is R-CHOP alone enough?
Julie Vose
Multiple Myeloma: Updates and options
Sagar Lonial
Multiple Myeloma: What do we do in early relapse?
Rafael Fonseca

Melanoma/Sarcoma/GU/GI
Melanoma: A new paradigm in adjuvant therapy
Sanjiv Agarwala
 
Soft Tissue Sarcoma
Shane Morita
RCC Update: Is immunotherapy front-line again?
Ravi Madan
What is the best first-line option for hormone resistant prostate cancer?
Donald Trump
Bladder Cancer: Where does immunotherapy fit in?
Ravi Madan
Updates in GI Cancers
Alan Venook
Lung/HNC
NSCLC: First-line treatment – Immunotherapy, combination chemoimmunotherapy, or targeted therapy?
Julie Brahmer
SCLC: Finally, something new!
Paul Bunn
Immunotherapy in HNSCC: Are we ready for a paradigm shift?
Hyunseok Kang

Breast Cancer
Updates in the treatment of hormone receptor positive breast cancer in early and late stage disease
Hope S. Rugo
Precision medicine meets breast oncology: Molecular testing to direct treatment decisions
William Gradishar
Optimal therapy for early stage HER2+ breast cancer: A new menu of options
Mark Pegram
Immunotherapy for breast cancer: When, in which patients and what's next?
Hope S. Rugo
New treatment options for metastatic HER2+ breast cancer
William Gradishar
Key meeting takeaways
Hope S. Rugo